Features
Derek Wallace, Global Dengue Program Head at Takeda Vaccine Business Unit, discusses the recent Phase 2 results showing its vaccine holds...
Dr Chris Barber, CEO of not-for-profit organisation and educational charity Lhasa Limited, discusses new innovations and ideas that are set to...
Increasingly collaborative efforts have seen the threat of HIV recede and brought hope to demographics and communities most vulnerable to the...
Greg Alton, Executive Vice President of Corporate and Medical Affairs at Gilead, reveals how the rapid development and distribution of HIV...
Brian Woodfall, Global Head of Late Development, Infectious Diseases at Janssen, explains why a future without HIV can only be achieved if...
For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation will have a dramatic impact – DIA's...
With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 EU member states are bidding to...
Transparency is becoming important across a whole range of industries but, for the pharmaceutical industry, it can mean life or death. Ben...
Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment is changed...
For every completed survey, £5 will be donated to charity. We invite you to participate in this short industry-wide survey which seeks to...
